Pretomanid is a nitroimidazopyran active againt Mycobacterium tuberculosis. It is active against multidrug-resistant M. tuberculosis clinical isolates with MIC <1 µg/ml. Pretomanid at 25, 50, and 100 mg/kg of body weight daily for 10 days or 60 days reduces the mycobacterial burden in both spleen and lung tissue in a mouse infection model. Pretomanid at 100 mg/kg in cyclodextrin/lecithin reduces the bacterial load below 500 CFU in the lungs and spleen. It is approved for use in combination treatment for drug-resistant, treatment-intolerant or non-responsive multidrug-resistant (MDR) Tuberculosis.